This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05617885
Recruitment Status : Active, not recruiting
First Posted : November 16, 2022
Last Update Posted : February 28, 2024
Eli Lilly and Company
Information provided by (Responsible Party):
Praful Ravi, MB BCHir, MRCP, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 1, 2024
Estimated Study Completion Date : June 1, 2026